tirzepatide cause death Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

29.47

★★★★☆4.8 (126)

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism

26.67

★★★★★4.9 (98)

Weight-loss drug tirzepatide may lower heart failure deaths

25.31

★★★★★5.0 (157)

New Cleveland Clinic research finds tirzepatide is associated with a 16% lower risk of major heart and kidney complications compared with dulaglutide in people with Type 2 diabetes and heart disease. The

24.00

★★★★★4.7 (84)

Tirzepatide may only temporarily quiet “food noise”

29.25

★★★★★4.9 (203)

Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT‐MMO trial - Lam - 2025 - Obesity

24.12

★★★★★5.0 (176)

Clinical Impact of Tirzepatide on Patients With OSA and Obesity

22.29

★★★★★4.8 (132)